Leukaemia - chronic lymphocytic leukaemia

The PBS subsidises idelalisib and obinutuzumab for patients with chronic lymphocytic leukaemia (CLL).

Treatment with idelalisib can be subsidised through the Pharmaceutical Benefits Scheme (PBS) under section 85 of the National Health Act 1953 for patients with CLL. Treatment with obinutuzumab can be subsidised through the PBS under section 100 of the National Health Act 1953 for patients with CLL.

Section 100 arrangements - obinutuzumab only

Obinutuzumab is only available to a patient who is attending:

  • an approved private hospital
  • a public participating hospital, or
  • a public hospital

and is a

  • day admitted patient
  • non-admitted patient, or
  • patient on discharge

This item is not PBS subsidised for hospital in-patients. You must include the hospital name and provider number on the authority application form.

Patient eligibility

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing idelalisib and obinutuzumab.

Applications

Initial treatment

Make all initial applications for authority approval to prescribe PBS subsidised idelalisib and obinutuzumab for the treatment of CLL in writing and:

Initial applications for idelalisib, including patients who received non-PBS subsidised idelalisib for the treatment of CLL before 1 September 2017, must include a completed:

Initial applications for obinutuzumab must include a completed:

Continuing treatment

To apply for continuing treatment contact the PBS Complex Drugs Programs enquiry line.

Further information

For more information contact the PBS Complex Drugs Programs enquiry line.

Page last updated: 15 February 2018